Control study of Ziprasidone and Risperidone on Efficacy and Cognitive Function in First-episode Schizophrenia

Abstract

Objective To compare the effect of ziprasidone and risperidone on the efficacy and cognitive function in first-episode schizophrenia.Methods 86 first-episode inpatients who met CCMD-3 diagnostic criteria for schizophrenia were randomly divided into study group(n = 42) and control group(n=44) for an 8-week observation.The study group received ziprasidone,while the control group was treated with risperidone.The Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Symptoms Scale(TESS) were used to evaluate the efficacy and side effects respectively before and after 2,4,6,8 week's treatment.WAIS-R,WMS,WCST were adopted to evaluate the cognitive function before and after treatment.Results There were significant difference in the total scores of PANSS of the two group after treatment than before(P＜0.01).The effective rate of ziprasidone group was 92.5%,in which 80% were improved remarkably.The effective rate of risperidone group was 90%,in which 80% were improved remarkably.There were significant difference in curative effect between the two groups(P＞0.05).The scores of TESS of study group were significantly lower than those of control group at 6,8 weekend(P＜0.01).The scores of WAIS-R language scale,operation scale,total scale,memory quotient(MQ),total trials,persistent errors and random errors of W CST were improved significantly in two group compared with before treatment(P ＜ 0.05 or P ＜ 0.01).After the treatment,there was remarkable difference on the scores of MQ and persistent errors in study group compared with those in control group(P＜0.05).Conclusion Ziprasidone is a safe and effective atypical antipsychotics,and it's curative effect is similar to risperidone.However,ziprasidone has few and slight side effects as well as the improvement of the cognitive function of first-episode schizophrenia obviously,it can be used as choice drug for first-episode schizophrenia. Key words: Ziprasidone; Risperidone; Schizophrenia; Cognitive function